Bionik Laboratories Corp. (BNKL)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
May 9, 2025, 4:00 PM EDT
Bionik Laboratories Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2014 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | 2014 - 2018 |
| Revenue | 1.81 | 1.27 | 1.19 | 2.15 | 3.25 | Upgrade
|
| Revenue Growth (YoY) | 41.73% | 6.73% | -44.58% | -33.66% | 228.74% | Upgrade
|
| Cost of Revenue | 0.82 | 0.32 | 0.27 | 0.89 | 1.63 | Upgrade
|
| Gross Profit | 0.99 | 0.95 | 0.92 | 1.26 | 1.62 | Upgrade
|
| Selling, General & Admin | 4.86 | 4.73 | 5.53 | 6.75 | 6.23 | Upgrade
|
| Research & Development | 0.9 | 1 | 1.54 | 3.89 | 3.17 | Upgrade
|
| Operating Expenses | 5.76 | 5.73 | 7.08 | 12.42 | 11.1 | Upgrade
|
| Operating Income | -4.77 | -4.77 | -6.16 | -11.16 | -9.49 | Upgrade
|
| Interest Expense | -0.11 | -0.83 | -0.41 | -0.18 | -3.27 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | -0.11 | 0.12 | 0.25 | 1.86 | Upgrade
|
| EBT Excluding Unusual Items | -4.89 | -5.71 | -6.44 | -11.09 | -10.89 | Upgrade
|
| Merger & Restructuring Charges | -0.05 | - | - | - | - | Upgrade
|
| Impairment of Goodwill | - | -4.28 | -6.8 | -11.22 | - | Upgrade
|
| Asset Writedown | - | -0.92 | -0.38 | -2.7 | - | Upgrade
|
| Other Unusual Items | - | 0.5 | - | - | 0.34 | Upgrade
|
| Pretax Income | -4.95 | -10.41 | -13.62 | -25.02 | -10.56 | Upgrade
|
| Net Income | -4.95 | -10.41 | -13.62 | -25.02 | -10.56 | Upgrade
|
| Net Income to Common | -4.95 | -10.41 | -13.62 | -25.02 | -10.56 | Upgrade
|
| Shares Outstanding (Basic) | 7 | 6 | 5 | 4 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 7 | 6 | 5 | 4 | 2 | Upgrade
|
| Shares Change (YoY) | 18.13% | 13.95% | 15.10% | 88.55% | 251.02% | Upgrade
|
| EPS (Basic) | -0.72 | -1.78 | -2.66 | -5.61 | -4.47 | Upgrade
|
| EPS (Diluted) | -0.72 | -1.78 | -2.66 | -5.61 | -4.47 | Upgrade
|
| Free Cash Flow | -3.4 | -4.16 | -4.62 | -9.22 | -9.33 | Upgrade
|
| Free Cash Flow Per Share | -0.49 | -0.71 | -0.90 | -2.07 | -3.95 | Upgrade
|
| Gross Margin | 54.84% | 74.84% | 77.41% | 58.51% | 49.78% | Upgrade
|
| Operating Margin | -264.40% | -374.70% | -515.76% | -518.45% | -292.28% | Upgrade
|
| Profit Margin | -273.99% | -817.14% | -1141.29% | -1161.75% | -325.21% | Upgrade
|
| Free Cash Flow Margin | -188.12% | -326.59% | -387.44% | -428.32% | -287.56% | Upgrade
|
| EBITDA | -4.71 | -4.67 | -5.97 | -10.78 | -9.14 | Upgrade
|
| EBITDA Margin | -260.90% | - | - | - | -281.55% | Upgrade
|
| D&A For EBITDA | 0.06 | 0.1 | 0.19 | 0.38 | 0.35 | Upgrade
|
| EBIT | -4.77 | -4.77 | -6.16 | -11.16 | -9.49 | Upgrade
|
| EBIT Margin | -264.40% | - | - | - | -292.28% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.